Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study

Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study

Primary results from the phase 3 RESONATE-2 study demonstrated superior efficacy and tolerability with ibrutinib versus chlorambucil in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Here, we describe characteristics and outcomes of patients who received ibrutinib...

Full description

Bibliographic Details
Main Authors: Jennifer A. Woyach, Paul M. Barr, Thomas J. Kipps, Jacqueline C. Barrientos, Inhye E. Ahn, Paolo Ghia, Vincent Girardi, Emily Hsu, Mandy Jermain, Jan A. Burger
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Cancers
Subjects:
ibrutinib
chronic lymphocytic leukemia
long-term outcomes
Online Access:https://www.mdpi.com/2072-6694/15/2/507

Internet

https://www.mdpi.com/2072-6694/15/2/507

Similar Items